Disitamab vedotin plus programmed death-1 inhibitor for pre-treated HER2 overexpressed advanced gastric cancer: a multicentre retrospective real-world study

Background The efficacy of pre-treated advanced gastric or gastroesophageal junction cancer (G/GEJC) with HER2 overexpressed (IHC 2+/3+) remains unsatisfactory. This retrospective real-world study aimed to analyse the safety and efficacy of disitamab vedotin (RC48) plus programmed death-1 (PD-1) inh...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Xiao Yan, Zhong Xie, Kaobin Ouyang, Mingyu Lai, Li Yang, Tianying Huang, Fengping Li, Huayuan Liang, Kaihua Huang, Zhiwei Li, Qing Xie, Rou Zhong, Huimin Zhang, Min Lai, Miaozhen Qiu, Liying Zhao
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2025-12-01
Edice:	Annals of Medicine
Témata:	Gastric cancer HER2 disitamab vedotin PD-1 inhibitor real world
On-line přístup:	https://www.tandfonline.com/doi/10.1080/07853890.2025.2569994
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!